Загрузка...
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Lenalidomide and azacitidine each have activity in myelodysplastic syndromes (MDS) patients, where both microenvironment and cell-regulatory mechanisms contribute to disease pathogenesis. The objective of this multicenter, phase 2 expansion trial was to determine the efficacy and safety of combinati...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3525020/ https://ncbi.nlm.nih.gov/pubmed/22915641 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-06-434639 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|